Viking Therapeutics’ collaboration with Ligand Pharmaceuticals has sailed into some trouble, with one of the partners keen to jettison part of the pact. The two companies’ relationship dates back to ...

Under the terms, Ligand will pay $39 a share in cash for Xoma, a 2.9% premium over the $37.90 closing price on Friday. The deal is expected to close in the third quarter.

April 27 (Reuters) - Ligand Pharmaceuticals (LGND.O), opens new tab will buy fellow biotechnology royalty aggregator XOMA Royalty (XOMA.O), opens new tab for about $739 million in cash, the companies ...

After Xoma Royalty went on a dealmaking spree last year, the biotech royalty aggregator is now itself being bought out by its peer Ligand Pharmaceuticals. On Monday, Ligand announced plans to acquire ...

Ligand Pharmaceuticals continues to outperform, driven by its high-margin, diversified royalty model and disciplined investment approach. LGND’s transition in 2022 to a capital and technology provider ...

Department of Chemistry & Biochemistry, Colleges of Science & Medicine, University of Arizona, Tucson, United States Department of Pharmacology & Toxicology, R Ken Coit College of Pharmacy, University ...

Safety and efficacy of pembrolizumab and epacadostat combination therapy in metastatic epithelial-derived cancers: A systematic review and meta-analysis of randomized controlled trials. Preclinical ...

Abstract: Predicting protein-ligand binding affinities is a critical problem in drug discovery and design. A majority of existing methods fail to accurately characterize and exploit the geometrically ...

ABSTRACT: Background: The Coronavirus disease 2019 (COVID-19) pandemic, caused by the SARS-CoV-2 coronavirus, remains a global threat despite lifting the health emergency. Scientists from all ...

PELSA allows for systematic analysis of ligand-binding proteins, their binding sites, and local binding affinities in cell lysate. Credit: DICP PELSA is a sensitive, versatile method for identifying ...